Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 6.71 billion. The enterprise value is 7.62 billion.

Market Cap	6.71B
Enterprise Value	7.62B

Important Dates

The last earnings date was Wednesday, November 12, 2025.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 207.20 million shares outstanding. The number of shares has increased by 0.52% in one year.

Current Share Class	207.20M
Shares Outstanding	207.20M
Shares Change (YoY)	+0.52%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	1.33%
Owned by Institutions (%)	0.20%
Float	117.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.33
PB Ratio	4.09
P/TBV Ratio	4.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-15.88
EV / Sales	11.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-25.97

Financial Position

The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.68.

Current Ratio	0.75
Quick Ratio	0.38
Debt / Equity	0.68
Debt / EBITDA	n/a
Debt / FCF	-3.82
Interest Coverage	-15.78

Financial Efficiency

Return on equity (ROE) is -25.65% and return on invested capital (ROIC) is -9.59%.

Return on Equity (ROE)	-25.65%
Return on Assets (ROA)	-8.14%
Return on Invested Capital (ROIC)	-9.59%
Return on Capital Employed (ROCE)	-19.71%
Revenue Per Employee	1.68M
Profits Per Employee	-1.24M
Employee Count	387
Asset Turnover	0.19
Inventory Turnover	9.97

Taxes

Income Tax	-9.60M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.95% in the last 52 weeks. The beta is 0.51, so Mycenax Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	-28.95%
50-Day Moving Average	34.26
200-Day Moving Average	36.84
Relative Strength Index (RSI)	45.15
Average Volume (20 Days)	181,207

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 649.64 million and -479.46 million in losses. Loss per share was -2.32.

Revenue	649.64M
Gross Profit	-221.69M
Operating Income	-443.32M
Pretax Income	-489.07M
Net Income	-479.46M
EBITDA	-203.95M
EBIT	-443.32M
Loss Per Share	-2.32

Full Income Statement

Balance Sheet

The company has 217.79 million in cash and 1.12 billion in debt, giving a net cash position of -902.91 million or -4.36 per share.

Cash & Cash Equivalents	217.79M
Total Debt	1.12B
Net Cash	-902.91M
Net Cash Per Share	-4.36
Equity (Book Value)	1.64B
Book Value Per Share	7.93
Working Capital	-275.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -170.31 million and capital expenditures -122.94 million, giving a free cash flow of -293.24 million.

Operating Cash Flow	-170.31M
Capital Expenditures	-122.94M
Free Cash Flow	-293.24M
FCF Per Share	-1.42

Full Cash Flow Statement

Margins

Gross margin is -34.12%, with operating and profit margins of -68.24% and -73.80%.

Gross Margin	-34.12%
Operating Margin	-68.24%
Pretax Margin	-75.28%
Profit Margin	-73.80%
EBITDA Margin	-31.39%
EBIT Margin	-68.24%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.52%
Shareholder Yield	-0.52%
Earnings Yield	-7.14%
FCF Yield	-4.37%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 2.42 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.42
Piotroski F-Score	4